Back
Deciphera Pharmaceuticals Quote, Financials, Valuation and Earnings
NOW is the time to get in on this trillion-dollar megatrend
Get it here.
Sell
25
DCPH
Deciphera Pharmaceuticals
Last Price:
14.66
Seasonality Move:
6.77%
7 Day Trial
ALL ACCESS PASS
$
7
BREAKING: Elon Musk's Secret A.I. Project Set to Plunge Millions of Americans Into Poverty
Click here now to prepare yourself for what's around the cornerDeciphera Pharmaceuticals Price Quote
$14.66
+0.01 (+3.39%)
(Updated: April 27, 2024 at 6:01 AM ET)
Deciphera Pharmaceuticals Key Stats
Sell
25
Deciphera Pharmaceuticals (DCPH)
is a Sell
Day range:
$14.09 - $14.84
52-week range:
$9.90 - $17.73
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.63
P/B ratio:
3.37%
Volume:
329.8K
Avg. volume:
507K
1-year change:
1.81%
Market cap:
$1.2B
Revenue:
$163.4M
EPS:
$-2.29
How Much Does Deciphera Pharmaceuticals Make?
-
How Much Are Deciphera Pharmaceuticals's Sales Annually?
DCPH Revenues are $163.4M -
How Much Profit Does Deciphera Pharmaceuticals's Make A Year?
DCPH net income is -$194.9M
Is Deciphera Pharmaceuticals Growing As A Company?
-
What Is Deciphera Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.33% -
What Is Deciphera Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Deciphera Pharmaceuticals Stock Price Performance
-
Did Deciphera Pharmaceuticals Stock Go Up Last Month?
Deciphera Pharmaceuticals share price went down by -1.15% last month -
Did DCPH's Share Price Rise Over The Last Year?
DCPH share price rose by 1.81% over the past 1 year
What Is Deciphera Pharmaceuticals 52-Week High & Low?
-
What Is Deciphera Pharmaceuticals’s 52-Week High Share Price?
Deciphera Pharmaceuticals has traded as high as $17.73 over the past 52 weeks -
What Is Deciphera Pharmaceuticals’s 52-Week Low Share Price?
Deciphera Pharmaceuticals has traded as low as $9.90 over the past 52 weeks
Deciphera Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Deciphera Pharmaceuticals?
-
How Much Debt Does Deciphera Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Deciphera Pharmaceuticals Have?
Cash and short term investments quarterly total is $306.2M -
What Is Deciphera Pharmaceuticals’s Book Value Per Share?
Book value per share is 4.36
Is Deciphera Pharmaceuticals Cash Flow Positive?
-
What Is DCPH Cash Flow From Operations?
Cash flow from operations (TTM) is -$146.7M -
What Is Deciphera Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $152M -
What Is Deciphera Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is $12.5M
Deciphera Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
DCPH return on invested capital is -50.8% -
What Is Deciphera Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -39.24% -
What Is DCPH Return On Equity?
ROE is a measure of profitability and is -50.8%
Deciphera Pharmaceuticals Earnings Date & Stock Price
-
What Is Deciphera Pharmaceuticals's Stock Price Today?
A single share of DCPH can be purchased today for 14.65 -
What Is Deciphera Pharmaceuticals’s Stock Symbol?
Deciphera Pharmaceuticals trades on the nasdaq under the ticker symbol: DCPH -
When Is Deciphera Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Deciphera Pharmaceuticals is scheduled on May 3, 2024 -
When Is DCPH's next ex-dividend date?
Deciphera Pharmaceuticals's next ex-dividend date is June 16, 2020 -
How To Buy Deciphera Pharmaceuticals Stock?
You can buy Deciphera Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Deciphera Pharmaceuticals Competitors
-
Who Are Deciphera Pharmaceuticals's Competitors?
Below is a list of companies who compete with Deciphera Pharmaceuticals or are related in some way:
Deciphera Pharmaceuticals Dividend Yield
Data Unavailable
Deciphera Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 7.95% |
| Revenue: | 32.88% | 3.19% |
Analyst Recommendations
| Buy Recommendations: | 5 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 24.20 |
| Upside from Last Price: | 65.19% |